Navigation Links
Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
Date:10/14/2010

BETHESDA, Md., Oct. 14 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York.

Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company's DCVax® technology and unprecedented long-term clinical trial results.

There will be a corresponding live webcast of the conference, which can be accessed by visiting http://www.mdbpartners.com/vaccine.

Hosted by MD Becker Partners and BioBusiness.TV, the Cancer Immunotherapy: A Long-Awaited Reality conference includes keynote speakers, panelist and plenary sessions, company presentations, and intimate networking opportunities to meet the needs of all attendees.  Pre-registration is required and attendance is limited to 150 individuals.  To register, or to obtain more information, please visit http://www.mdbpartners.com/vaccine or contact MD Becker Partners directly at info@mdbpartners.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis.  The Company has two broad platform technologies:  dendritic cell-based vaccines and therapeutic antibodies.  The Company's lead clinical trial is a 240-patient Phase II trial in GBM.  The Company also previously received clearance from the FDA for a 600+ patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  The Company's second technology platform, involving antibodies to CXCR4, is at the pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

About MD Becker Partners

MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry.   The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies.  As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business.  To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics.  For more information visit http://www.mdbpartners.com.

About BioBusiness.TV

BioBusiness.TV is the first independent Internet TV Network for Life Sciences Investors and Executives.  The company creates video-based, industry focused business news and analysis programs.  BioBusiness.TV produces and syndicates videos ranging from news and stock picks, to equity analyst insights, as well as C-level executive interviews on strategy, management, policy, marketing, science, and more.  BioBusiness.TV's latest Original Series, "The Stem Cell Review," is a 10-part TV program on the science, medical applications, and business of stem cells, which provides a clear and concise understanding of the state of stem cells today, with the additional depth and expertise you would come to expect from the most renowned authorities in the field.  For more information, visit http://www.biobusiness.tv.


'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
2. Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors
3. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
4. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Sirius Genomics to Present at Invest Northwest Conference
10. Northwest Biotherapeutics Secures $700,000 Equity Financing
11. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... YORK , January 20, 2017 ... Organization, cancer is one of leading causes of death ... 2012. Although the number of cancer related deaths increased ... 1990. Rising in incidence rate of various cancers continues ... to a research report by Global Market Insights, Inc. ...
(Date:1/19/2017)... Jan. 19, 2017  Market Research Future has a half cooked ... Liquid Biopsy is growing rapidly and expected to reach USD 450 ... Highlights ... Liquid Biopsy Market has been assessed as a swiftly growing market ... boom in the coming future. There has been a tremendous growth ...
(Date:1/19/2017)... Research and Markets ... the addition of the "Implantable Biomaterials Market Analysis ... report to their offering. Report Highlights: ... on current and future market trends to identify the investment opportunities ... base numbers Key market trends across the business segments, ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CESĀ® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/16/2016)... 16, 2016 Research and Markets has announced ... Global Forecast to 2021" report to their offering. ... The biometric vehicle access ... a CAGR of 14.06% from 2016 to 2021. The market is ... to reach 854.8 Million by 2021. The growth of the biometric ...
Breaking Biology News(10 mins):